{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:20:04Z","timestamp":1765534804746,"version":"3.48.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ningbo Medical and Health Brand Discipline","award":["2022-F01"],"award-info":[{"award-number":["2022-F01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01366-x","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:15:16Z","timestamp":1765534516000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Neoadjuvant Chemotherapy on Perioperative Tumor Marker Dynamics and Postoperative Recovery in Patients Undergoing Laparoscopic Radical Resection for Rectal Cancer"],"prefix":"10.1007","volume":"56","author":[{"given":"Leibin","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglei","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangbin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"10","key":"1366_CR1","doi-asserted-by":"publisher","first-page":"101231","DOI":"10.1016\/j.xcrm.2023.101231","volume":"4","author":"P Qin","year":"2023","unstructured":"Qin P, Chen H, Wang Y, et al. Cancer-associated fibroblasts undergoing neoadjuvant chemotherapy suppress rectal cancer revealed by single-cell and Spatial transcriptomics. Cell Rep Med. 2023;4(10):101231. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101231.","journal-title":"Cell Rep Med"},{"issue":"10","key":"1366_CR2","doi-asserted-by":"publisher","first-page":"101232","DOI":"10.1016\/j.xcrm.2023.101232","volume":"4","author":"JA Shyer","year":"2023","unstructured":"Shyer JA, Turley SJ, Vermeulen L. Resolving the tissue response to neoadjuvant chemotherapy in rectal cancer. Cell Rep Med. 2023;4(10):101232. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101232.","journal-title":"Cell Rep Med"},{"issue":"10","key":"1366_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.medj.2024.07.002","volume":"5","author":"Z Yang","year":"2024","unstructured":"Yang Z, Ma J, Han J, et al. Gut Microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer. Med. 2024;5(10):1293\u2013e13061294. https:\/\/doi.org\/10.1016\/j.medj.2024.07.002.","journal-title":"Med"},{"issue":"1","key":"1366_CR4","doi-asserted-by":"publisher","first-page":"e2350903","DOI":"10.1001\/jamanetworkopen.2023.50903","volume":"7","author":"HM Thompson","year":"2024","unstructured":"Thompson HM, Omer DM, Lin S, et al. Organ preservation and survival by clinical response grade in patients with rectal cancer treated with total neoadjuvant therapy: A secondary analysis of the OPRA randomized clinical trial. JAMA Netw Open. 2024;7(1):e2350903. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.50903.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"1366_CR5","doi-asserted-by":"publisher","first-page":"e2414702","DOI":"10.1001\/jamanetworkopen.2024.14702","volume":"7","author":"G Turri","year":"2024","unstructured":"Turri G, Ostuzzi G, Vita G, et al. Treatment of locally advanced rectal cancer in the era of total neoadjuvant therapy: A systematic review and network Meta-Analysis. JAMA Netw Open. 2024;7(6):e2414702. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.14702.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1366_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/s2468-1253(22)00439-3","volume":"8","author":"G Chen","year":"2023","unstructured":"Chen G, Jin Y, Guan WL, et al. Neoadjuvant PD-1 Blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 2023;8(5):422\u201331. https:\/\/doi.org\/10.1016\/s2468-1253(22)00439-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1366_CR7","doi-asserted-by":"publisher","unstructured":"Smith HG, Nilsson PJ, Shogan BD, et al. Neoadjuvant treatment of colorectal cancer: comprehensive review. BJS Open. 2024;8(3). https:\/\/doi.org\/10.1093\/bjsopen\/zrae038.","DOI":"10.1093\/bjsopen\/zrae038"},{"key":"1366_CR8","doi-asserted-by":"publisher","first-page":"1120684","DOI":"10.3389\/fimmu.2023.1120684","volume":"14","author":"J Zhu","year":"2023","unstructured":"Zhu J, Lian J, Xu B, et al. Neoadjuvant immunotherapy for colorectal cancer: right regimens, right patients, right directions? Front Immunol. 2023;14:1120684. https:\/\/doi.org\/10.3389\/fimmu.2023.1120684.","journal-title":"Front Immunol"},{"issue":"6","key":"1366_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41575-024-00900-9","volume":"21","author":"Y Kagawa","year":"2024","unstructured":"Kagawa Y, Smith JJ, Fokas E, et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21(6):444\u201355. https:\/\/doi.org\/10.1038\/s41575-024-00900-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1366_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.6004\/jnccn.2024.0041","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson AB, Venook AP, Adam M, et al. NCCN Guidelines\u00ae insights: rectal Cancer, version 3.2024. J Natl Compr Canc Netw. 2024;22(6):366\u201375. https:\/\/doi.org\/10.6004\/jnccn.2024.0041.","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"1366_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clcc.2024.06.001","volume":"23","author":"S Bedrikovetski","year":"2024","unstructured":"Bedrikovetski S, Traeger L, Seow W, et al. Oncological outcomes and response rate after total neoadjuvant therapy for locally advanced rectal cancer: A network Meta-Analysis comparing induction vs. Consolidation chemotherapy vs. Standard chemoradiation. Clin Colorectal Cancer. 2024;23(4):326\u2013e336329. https:\/\/doi.org\/10.1016\/j.clcc.2024.06.001.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"1366_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s12885-023-11103-x","volume":"23","author":"W Zhang","year":"2023","unstructured":"Zhang W, Zhou H, Jiang J, et al. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial. BMC Cancer. 2023;23(1):592. https:\/\/doi.org\/10.1186\/s12885-023-11103-x.","journal-title":"BMC Cancer"},{"key":"1366_CR13","doi-asserted-by":"publisher","unstructured":"Dapr\u00e0 V, Airoldi M, Bartolini M, et al. Total neoadjuvant treatment for locally advanced rectal cancer patients: where do we stand? Int J Mol Sci. 2023;24(15). https:\/\/doi.org\/10.3390\/ijms241512159.","DOI":"10.3390\/ijms241512159"},{"issue":"1","key":"1366_CR14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1186\/s12885-024-12972-6","volume":"24","author":"T Guo","year":"2024","unstructured":"Guo T, Liu K, Guo Y, et al. CapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more? BMC Cancer. 2024;24(1):1248. https:\/\/doi.org\/10.1186\/s12885-024-12972-6.","journal-title":"BMC Cancer"},{"issue":"1","key":"1366_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12876-025-03667-8","volume":"25","author":"Y Guo","year":"2025","unstructured":"Guo Y, Guo Z, Zhang J, et al. Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis. BMC Gastroenterol. 2025;25(1):87. https:\/\/doi.org\/10.1186\/s12876-025-03667-8.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"1366_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10151-024-02927-1","volume":"28","author":"R Gefen","year":"2024","unstructured":"Gefen R, Emile SH, Horesh N, Garoufalia Z, Freund MR, Wexner SD. When is neoadjuvant chemotherapy indicated in rectal neuroendocrine tumors? An analysis of the National cancer database. Tech Coloproctol. 2024;28(1):56. https:\/\/doi.org\/10.1007\/s10151-024-02927-1.","journal-title":"Tech Coloproctol"},{"issue":"10","key":"1366_CR17","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.3390\/curroncol30100655","volume":"30","author":"A Brignoli","year":"2023","unstructured":"Brignoli A, Ferrara E, Zannetti M, et al. Capecitabine-Induced ileitis during neoadjuvant pelvic Radio-Chemotherapy for locally advanced rectal cancer: A case report with literature review. Curr Oncol. 2023;30(10):9063\u201377. https:\/\/doi.org\/10.3390\/curroncol30100655.","journal-title":"Curr Oncol"},{"issue":"10","key":"1366_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","volume":"35","author":"T Conroy","year":"2024","unstructured":"Conroy T, Castan F, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):873\u201381. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.019.","journal-title":"Ann Oncol"},{"issue":"10","key":"1366_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","volume":"35","author":"ZY Lin","year":"2024","unstructured":"Lin ZY, Zhang P, Chi P, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024;35(10):882\u201391. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.015.","journal-title":"Ann Oncol"},{"issue":"1","key":"1366_CR20","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s00384-023-04433-6","volume":"38","author":"S Tan","year":"2023","unstructured":"Tan S, Ou Y, Huang S, Gao Q. Surgical, oncological, and functional outcomes of local and radical resection after neoadjuvant chemotherapy or chemoradiotherapy for early- and mid-stage rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38(1):132. https:\/\/doi.org\/10.1007\/s00384-023-04433-6.","journal-title":"Int J Colorectal Dis"},{"issue":"21","key":"1366_CR21","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1200\/jco.23.00903","volume":"41","author":"E Basch","year":"2023","unstructured":"Basch E, Dueck AC, Mitchell SA, et al. Patient-Reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (Alliance N1048). J Clin Oncol. 2023;41(21):3724\u201334. https:\/\/doi.org\/10.1200\/jco.23.00903.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1366_CR22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1200\/jco.22.00184","volume":"41","author":"HF Kennecke","year":"2023","unstructured":"Kennecke HF, O\u2019Callaghan CJ, Loree JM, et al. Neoadjuvant Chemotherapy, Excision, and observation for early rectal cancer: the phase II NEO trial (CCTG CO.28) primary end point results. J Clin Oncol. 2023;41(2):233\u201342. https:\/\/doi.org\/10.1200\/jco.22.00184.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1366_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ccell.2022.11.013","volume":"41","author":"H Teng","year":"2023","unstructured":"Teng H, Wang Y, Sui X, et al. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Cell. 2023;41(1):124\u2013e138126. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.013.","journal-title":"Cancer Cell"},{"issue":"28","key":"1366_CR24","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1200\/jco.24.01160","volume":"42","author":"AJ Scott","year":"2024","unstructured":"Scott AJ, Kennedy EB, Berlin J, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024;42(28):3355\u201375. https:\/\/doi.org\/10.1200\/jco.24.01160.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1366_CR25","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.21873\/anticanres.16777","volume":"43","author":"TW Ke","year":"2023","unstructured":"Ke TW, Chang SC, Liao YM, et al. Neoadjuvant chemotherapy With\/Without radiotherapy for locally advanced rectal cancer: A nationwide retrospective cohort study. Anticancer Res. 2023;43(12):5713\u201322. https:\/\/doi.org\/10.21873\/anticanres.16777.","journal-title":"Anticancer Res"},{"issue":"3","key":"1366_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s12029-022-00864-6","volume":"54","author":"P Nov","year":"2023","unstructured":"Nov P, Du K, Huang Z, et al. A Meta-analysis of total neoadjuvant therapies combining chemoradiotherapy with induction or consolidated chemotherapy for locally advanced rectal cancer. J Gastrointest Cancer. 2023;54(3):693\u2013702. https:\/\/doi.org\/10.1007\/s12029-022-00864-6.","journal-title":"J Gastrointest Cancer"},{"issue":"11","key":"1366_CR27","doi-asserted-by":"publisher","first-page":"8897","DOI":"10.1007\/s00432-023-04779-y","volume":"149","author":"J Wu","year":"2023","unstructured":"Wu J, Huang M, Wu Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation. J Cancer Res Clin Oncol. 2023;149(11):8897\u2013912. https:\/\/doi.org\/10.1007\/s00432-023-04779-y.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"1366_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.suc.2023.11.010","volume":"104","author":"D Affleck AGt, Herzig","year":"2024","unstructured":"Affleck AGt, Herzig D. Total neoadjuvant therapy for rectal cancer. Surg Clin North Am. 2024;104(3):609\u201317. https:\/\/doi.org\/10.1016\/j.suc.2023.11.010.","journal-title":"Surg Clin North Am"},{"issue":"6","key":"1366_CR29","doi-asserted-by":"publisher","first-page":"e2304619121","DOI":"10.1073\/pnas.2304619121","volume":"121","author":"Z Yu","year":"2024","unstructured":"Yu Z, Deng P, Chen Y, et al. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer. Proc Natl Acad Sci U S A. 2024;121(6):e2304619121. https:\/\/doi.org\/10.1073\/pnas.2304619121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1366_CR30","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/bjs\/znad120","volume":"110","author":"Q Wu","year":"2023","unstructured":"Wu Q, Zhou J, Huang J, et al. Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: bayesian network meta-analysis. Br J Surg. 2023;110(7):784\u201396. https:\/\/doi.org\/10.1093\/bjs\/znad120.","journal-title":"Br J Surg"},{"issue":"9","key":"1366_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41416-024-02652-4","volume":"130","author":"J Cai","year":"2024","unstructured":"Cai J, Lin K, Luo T, et al. Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial. Br J Cancer. 2024;130(9):1434\u201340. https:\/\/doi.org\/10.1038\/s41416-024-02652-4.","journal-title":"Br J Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01366-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:15:17Z","timestamp":1765534517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01366-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"30 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board and Ethics Committee of Ninghai Chengguan Hospital. Informed consent was waived due to its retrospective nature, as only de-identified patient data were used, which neither posed any potential harm nor affected patient care. This exemption complies with the regulatory and ethical guidelines for conducting retrospective research and was approved by both the Institutional Review Board and Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"238"}}